I was cogitating on what the CYDY investor/acquirer road show presentation might look like these days (that is if they're even doing such things). That led me to think about what values bigger cos. give to acquisition targets. I stumbled across this link that provides some good info for those trying to better understand values when these things go down.

I liked that you can sort by both premium and total consideration. As LL is likely considered a platform drug I wasn't sure that there were exact parallels within the data set but I still considered it somewhat edumacational.

As always, YMMV, but I'm interested in folks views on the state of the market and where we're at.

I also saw an article that said many/most acquisitions occur when the target drugs are in phase II trials. Here's our latest pipeline for reference .

Happy holidays!